Cue Biopharma Inc. (NASDAQ:CUE) saw its shares fall 5.4% in after-hours trading Tuesday after the company disclosed that four independent directors stepped down from its board.
The company said Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen resigned from the board effective May 29, 2026. The departures coincided with Cue Biopharma's stated move to align board composition with an emphasis on supporting late clinical-stage capabilities.
At the same time the company announced two new board appointments. Daniel Camardo, who is the former CEO of Athersys and currently serves as President of Immedica Pharma North America, was named to the board. The company also added Viola Meehan, who previously held the role of CFO at Vanqua Bio and has held senior finance positions at AbbVie and Abbott Laboratories.
The company outlined the professional backgrounds of the new directors. According to the disclosure, Camardo has more than 30 years of industry experience, including senior executive roles at Astellas Pharma, Clarus Therapeutics, and Horizon Therapeutics, where he served as Executive Vice President prior to that company's acquisition by Amgen in 2023. Meehan's resume was described as including over 30 years in finance roles and board service, encompassing positions at Federal Savings Bank and various biopharma organizations in addition to her roles at Vanqua Bio, AbbVie, and Abbott Laboratories.
Pasha Sarraf, chairman of the board, said the company is adding new perspectives to support its next stage of growth following recent strategic expansion of the pipeline and leadership team. Shao-Lee Lin, CEO and president of Cue Biopharma, stated that both new directors bring proven executive leadership and important skillsets including building organizations, leading commercial launches, and strategic finance experience.
Cue Biopharma is described in its filing as a precision immuno-engineering company focused on developing therapies for immunological disorders. The company did not provide additional commentary in the disclosure beyond the resignations, appointments, and the stated rationale of aligning governance to support its evolving clinical focus.
Summary
The departures of four independent directors and the appointment of two new board members coincide with Cue Biopharma's stated shift to bolster late clinical-stage capabilities; the stock declined in after-hours trading following the announcement.
Key points
- Four independent directors - Jill Broadfoot, Peter Kiener, Frank Morich, and Patrick Verheyen - resigned effective May 29, 2026.
- Two new directors, Daniel Camardo and Viola Meehan, were appointed to the board to support the company as it moves toward late clinical-stage capabilities.
- Shares of Cue Biopharma fell 5.4% in after-hours trading following the disclosure.
Risks and uncertainties
- Board turnover could create short-term governance uncertainty while the company integrates new directors - this may affect investor perception in the biotech and healthcare sectors.
- Management indicated a strategic shift toward late clinical-stage capabilities; execution of that transition and related leadership changes introduce operational uncertainty for the company and its development pipeline.
- The market reaction to governance changes, reflected in the after-hours price movement, highlights sensitivity in the stocks sector to board composition announcements.